Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise despite higher R&D expenses and a decline in operating margin.
Colts QB Richardson's injury raises durability concerns as analysts criticize his decision-making.
Under Armour's weak Q1 sales and tariff pressures lead to a plunge in its stock price.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise despite higher R&D expenses and a decline in operating margin.
Colts QB Richardson's injury raises durability concerns as analysts criticize his decision-making.
Under Armour's weak Q1 sales and tariff pressures lead to a plunge in its stock price.